

## SUPPLEMENTARY MATERIALS

### Supplementary Tables

Supplementary Table 1. Stay at home order dates by state/territory

| State                 | Month/Day/Year | Level  |
|-----------------------|----------------|--------|
| California            | 3/19/2020      | State  |
| Illinois              | 3/21/2020      | State  |
| New Jersey            | 3/21/2020      | State  |
| New York              | 3/22/2020      | State  |
| Connecticut           | 3/23/2020      | State  |
| Louisiana             | 3/23/2020      | State  |
| Ohio                  | 3/23/2020      | State  |
| Oregon                | 3/23/2020      | State  |
| Washington            | 3/23/2020      | State  |
| Delaware              | 3/24/2020      | State  |
| Indiana               | 3/24/2020      | State  |
| Massachusetts         | 3/24/2020      | State  |
| Michigan              | 3/24/2020      | State  |
| New Mexico            | 3/24/2020      | State  |
| West Virginia         | 3/24/2020      | State  |
| Hawaii                | 3/25/2020      | State  |
| Idaho                 | 3/25/2020      | State  |
| Oklahoma <sup>a</sup> | 3/25/2020      | City   |
| Vermont               | 3/25/2020      | State  |
| Wisconsin             | 3/25/2020      | State  |
| Colorado              | 3/26/2020      | State  |
| Minnesota             | 3/27/2020      | State  |
| New Hampshire         | 3/27/2020      | State  |
| Utah <sup>b</sup>     | 3/27/2020      | County |
| Alaska                | 3/28/2020      | State  |

|                       |           |        |
|-----------------------|-----------|--------|
| Montana               | 3/28/2020 | State  |
| Rhode Island          | 3/28/2020 | State  |
| Wyoming <sup>c</sup>  | 3/28/2020 | County |
| Kansas                | 3/30/2020 | State  |
| Maryland              | 3/30/2020 | State  |
| North Carolina        | 3/30/2020 | State  |
| Virginia              | 3/30/2020 | State  |
| Arizona               | 3/31/2020 | State  |
| Tennessee             | 3/31/2020 | State  |
| District of Columbia  | 4/1/2020  | State  |
| Nevada                | 4/1/2020  | State  |
| Pennsylvania          | 4/1/2020  | State  |
| Maine                 | 4/2/2020  | State  |
| Texas                 | 4/2/2020  | State  |
| Florida               | 4/3/2020  | State  |
| Georgia               | 4/3/2020  | State  |
| Mississippi           | 4/3/2020  | State  |
| Alabama               | 4/4/2020  | State  |
| Missouri              | 4/6/2020  | State  |
| South Carolina        | 4/7/2020  | State  |
| Kentucky <sup>d</sup> | —         | None   |
| Arkansas              | —         | None   |
| Iowa                  | —         | None   |
| Nebraska              | —         | None   |
| North Dakota          | —         | None   |
| South Dakota          | —         | None   |

<sup>a</sup> Oklahoma: initial stay at home/shelter in place orders were given to major cities, beginning with Norman (March 25), Oklahoma City (March 28), and Tulsa (March 28). — States with no date did not issue full stay-at-home orders statewide or in any major cities or counties.

<sup>b</sup> Utah: Initial stay at home orders were county-specific, starting with Summit County(March 27), Salt Lake County (March 30), and Davis County(April 1)

<sup>c</sup> Wyoming: Stay at home orders were county-specific, beginning with Jackson County (March 28)

<sup>d</sup> Kentucky: A state-level "healthy at home" recommendation was issued on March 26, but no full stay-at-home orders were issued.

Supplementary Table 2. Therapy classifications

| Sample and analysis                                   | Ordered classification process  |
|---|---|
| Main study sample, TTI analysis                       | Exclude any regimen that contained a drug that was given as part of a clinical trial (“Clinical Study Drug”)<br>Exclude any regimen that did not contain at least one systemic therapy listed on NCCN guidelines  |
| Sub-sample, treatment selection analysis <sup>a</sup> | Exclude any regimen that contained a targeted therapy, defined as: 1) EGFR, ALK, ROS1, BRAF targeted therapy in NSCLC cohort; 2) PD-L1 monotherapy (for presumed MSI-high) or PARP inhibitor therapy (for presumed HRD-positive) prostate cancer; 3) FGFR targeted therapy in urothelial cancer; 4) HER-2 targeted therapy in breast cancer<br>Classify as myelosuppressive (containing at least one cytotoxic chemotherapy or a cyclin-dependent kinase inhibitor) or non-myelosuppressive |

<sup>a</sup>These treatment designations applied only to the sub-sample of patients diagnosed with advanced breast, prostate, urothelial, or non-small cell lung cancer. NSCLC = non-small cell lung cancer, NCCN = National Comprehensive Cancer Network®, MSI = microsatellite instability, PARP = Poly (ADP-ribose) polymerase, HRD = Homologous recombination deficiency

Supplementary Table 3. Population characteristics for Treatment Selection Analysis

| Variable                         | 2019                    |                          |       | 2020                    |                          |       | Total<br>(n=5962) |
|----------------------------------|-------------------------|--------------------------|-------|-------------------------|--------------------------|-------|-------------------|
|                                  | Jan 1-Mar 8<br>(n=1246) | Apr 8-Jul 31<br>(n=1949) | SMD   | Jan 1-Mar 8<br>(n=1121) | Apr 8-Jul 31<br>(n=1646) | SMD   |                   |
| Cancer, No. (%)                  |                         |                          |       |                         |                          |       |                   |
| Breast                           | 238 (19.1)              | 391 (20.1)               | 0.079 | 194 (17.3)              | 278 (16.9)               | 0.070 | 1101 (18.5)       |
| NSCLC                            | 715 (57.4)              | 1146 (58.8)              |       | 684 (61.0)              | 973 (59.1)               |       | 3518 (59.0)       |
| Prostate                         | 191 (15.3)              | 246 (12.6)               |       | 140 (12.5)              | 245 (14.9)               |       | 822 (13.8)        |
| UCC                              | 102 (8.2)               | 166 (8.5)                |       | 103 (9.2)               | 150 (9.1)                |       | 521 (8.7)         |
| Median Age (IQR), years          | 70 (63, 77)             | 71 (62, 78)              | 0.023 | 69 (62, 77)             | 70 (63, 78)              | 0.073 | 70 (63, 78)       |
| Gender, No. (%)                  |                         |                          |       |                         |                          |       |                   |
| Female                           | 557 (44.7)              | 964 (49.5)               | 0.095 | 536 (47.8)              | 768 (46.7)               | 0.023 | 2825 (47.4)       |
| Male                             | 689 (55.3)              | 985 (50.5)               |       | 585 (52.2)              | 878 (53.3)               |       | 3137 (52.6)       |
| Race, No. (%)                    |                         |                          |       |                         |                          |       |                   |
| Hispanic                         | 58 (5.2)                | 85 (4.9)                 |       | 45 (4.6)                | 70 (4.8)                 |       | 258 (4.9)         |
| Non-Hispanic Black               | 109 (9.8)               | 170 (9.8)                |       | 112 (11.4)              | 141 (9.7)                |       | 532 (10.1)        |
| Non-Hispanic White               | 801 (71.8)              | 1246 (71.9)              | 0.014 | 679 (69.1)              | 1016 (69.7)              | 0.059 | 3742 (70.8)       |
| Other                            | 147 (13.2)              | 231 (13.3)               |       | 146 (14.9)              | 230 (15.8)               |       | 754 (14.3)        |
| Missing                          | 131                     | 217                      |       | 139                     | 189                      |       | 676               |
| Insurance, No. (%)               |                         |                          |       |                         |                          |       |                   |
| Commercial                       | 597 (47.9)              | 973 (49.9)               | 0.07  | 575 (51.3)              | 817 (49.6)               | 0.044 | 2962 (49.7)       |
| Government                       | 263 (21.1)              | 434 (22.3)               |       | 243 (21.7)              | 352 (21.4)               |       | 1292 (21.7)       |
| Unknown/not documented/self-pay  | 386 (31.0)              | 542 (27.8)               |       | 303 (27.0)              | 477 (29.0)               |       | 1708 (28.6)       |
| Practice type, No. (%)           |                         |                          |       |                         |                          |       |                   |
| Academic                         | 95 (7.6)                | 154 (7.9)                | 0.01  | 66 (5.9)                | 104 (6.3)                | 0.018 | 419 (7.0)         |
| Community                        | 1151 (92.4)             | 1795 (92.1)              |       | 1055 (94.1)             | 1542 (93.7)              |       | 5543 (93.0)       |
| ECOG performance status, No. (%) |                         |                          |       |                         |                          |       |                   |
| 0-1                              | 543 (83.5)              | 780 (81.4)               | 0.056 | 505 (82.9)              | 728 (82.0)               | 0.025 | 2556 (82.3)       |
| ≥2                               | 107 (16.5)              | 178 (18.6)               |       | 104 (17.1)              | 160 (18.0)               |       | 549 (17.7)        |

|                              |            |             |       |            |            |       |             |
|------------------------------|------------|-------------|-------|------------|------------|-------|-------------|
| Missing                      | 596        | 991 (50.8)  |       | 512 (45.7) | 758 (46.1) |       | 2857 (47.9) |
| Opioid prescription, No. (%) | 77 (6.2)   | 120 (6.2)   | 0.001 | 63 (5.6)   | 90 (5.5)   | 0.007 | 350 (5.9)   |
| De novo metastatic, No. (%)  | 638 (57.3) | 1057 (60.5) | 0.066 | 613 (60.2) | 967 (65.6) | 0.113 | 3275 (61.2) |
| Missing                      | 132        | 202         |       | 102        | 172        |       | 608         |

<sup>a</sup> NSCLC = Non-small cell lung carcinoma; UCC = urothelial cell carcinoma; ECOG = Eastern Cooperative Oncology Group; SMD=standardized mean difference

Supplementary Table 4. Adjusted probabilities of treatment within 30 days by race and ethnicity

| Category           | 2019                    |                         |                           | 2020                    |                         |                           | Difference in differences |
|--------------------|-------------------------|-------------------------|---------------------------|-------------------------|-------------------------|---------------------------|---------------------------|
|                    | Jan 1-Mar 8             | Apr 8-Jul 31            | Difference                | Jan 1-Mar 8             | Apr 8-Jul 31            | Difference                | 2020-2019                 |
|                    | Est (95% CI)            | Est (95% CI)            | Est (95% CI)              | Est (95% CI)            | Est (95% CI)            | Est (95% CI)              | Est (95% CI)              |
| Hispanic           | 0.405<br>(0.215, 0.596) | 0.414<br>(0.286, 0.542) | 0.009<br>(-0.105, 0.122)  | 0.395<br>(0.209, 0.581) | 0.466<br>(0.206, 0.727) | 0.071<br>(-0.038, 0.180)  | 0.063<br>(-0.122, 0.247)  |
| Non-Hispanic Black | 0.395<br>(0.103, 0.687) | 0.386<br>(0.204, 0.568) | -0.009<br>(-0.150, 0.133) | 0.460<br>(0.275, 0.646) | 0.431<br>(0.173, 0.690) | -0.029<br>(-0.166, 0.108) | -0.021<br>(-0.285, 0.244) |
| Non-Hispanic White | 0.422<br>(0.308, 0.536) | 0.429<br>(0.318, 0.540) | 0.007<br>(-0.027, 0.041)  | 0.446<br>(0.282, 0.610) | 0.468<br>(0.359, 0.577) | 0.022<br>(-0.056, 0.099)  | 0.015<br>(-0.062, 0.092)  |
| Other              | 0.411<br>(0.177, 0.645) | 0.440<br>(0.259, 0.622) | 0.029<br>(-0.057, 0.116)  | 0.450<br>(0.162, 0.738) | 0.490<br>(0.265, 0.714) | 0.039<br>(-0.045, 0.124)  | 0.010<br>(-0.050, 0.070)  |

<sup>a</sup> Results are from race:period interaction model. CI = confidence interval

Supplementary Table 5. Adjusted probabilities of treatment within 30 days by age

| Category      | 2019                    |                         |                          | 2020                    |                         |                          | Difference in differences |
|---------------|-------------------------|-------------------------|--------------------------|-------------------------|-------------------------|--------------------------|---------------------------|
|               | Jan 1-Mar 8             | Apr 8-Jul 31            | Difference               | Jan 1-Mar 8             | Apr 8-Jul 31            | Difference               | 2020-2019                 |
|               | Est (95% CI)            | Est (95% CI)            | Est (95% CI)             | Est (95% CI)            | Est (95% CI)            | Est (95% CI)             | Est (95% CI)              |
| Age >75 years | 0.379<br>(0.279, 0.479) | 0.388<br>(0.304, 0.471) | 0.009<br>(-0.043, 0.061) | 0.412<br>(0.254, 0.570) | 0.445<br>(0.321, 0.570) | 0.033<br>(-0.028, 0.094) | 0.024<br>(-0.042, 0.091)  |
| Age ≤75 years | 0.432<br>(0.308, 0.556) | 0.441<br>(0.326, 0.557) | 0.009<br>(-0.043, 0.060) | 0.459<br>(0.309, 0.609) | 0.478<br>(0.339, 0.616) | 0.019<br>(-0.025, 0.062) | 0.010<br>(-0.043, 0.062)  |

<sup>a</sup>Results are from age:period interaction model. CI = confidence interval

Supplementary Table 6. Adjusted probabilities of receiving myelosuppressive therapy by race and ethnicity

| Category           | 2019                    |                         |                           | 2020                    |                         |                           | Difference in difference  |
|--------------------|-------------------------|-------------------------|---------------------------|-------------------------|-------------------------|---------------------------|---------------------------|
|                    | Jan 1-Mar 8             | Apr 8-Jul 31            | Difference                | Jan 1-Mar 8             | Apr 8-Jul 31            | Difference                | 2020-2019                 |
|                    | Est (95% CI)            | Est (95% CI)            | Est (95% CI)              | Est (95% CI)            | Est (95% CI)            | Est (95% CI)              | Est (95% CI)              |
| Hispanic           | 0.696<br>(0.591, 0.801) | 0.711<br>(0.625, 0.798) | 0.015<br>(-0.094, 0.125)  | 0.662<br>(0.559, 0.764) | 0.586<br>(0.491, 0.682) | -0.075<br>(-0.193, 0.042) | -0.091<br>(-0.245, 0.063) |
| Non-Hispanic Black | 0.711<br>(0.639, 0.783) | 0.696<br>(0.613, 0.778) | -0.016<br>(-0.102, 0.071) | 0.706<br>(0.639, 0.773) | 0.660<br>(0.584, 0.735) | -0.047<br>(-0.118, 0.025) | -0.031<br>(-0.134, 0.072) |
| Non-Hispanic White | 0.705<br>(0.660, 0.751) | 0.672<br>(0.620, 0.724) | -0.034<br>(-0.072, 0.005) | 0.684<br>(0.653, 0.714) | 0.683<br>(0.651, 0.716) | 0.000<br>(-0.031, 0.030)  | 0.033<br>(-0.017, 0.084)  |
| Other              | 0.657<br>(0.566, 0.748) | 0.608<br>(0.461, 0.755) | -0.049<br>(-0.157, 0.059) | 0.667<br>(0.576, 0.758) | 0.629<br>(0.524, 0.734) | -0.038<br>(-0.092, 0.016) | 0.011<br>(-0.104, 0.126)  |

<sup>a</sup> Results are from race:period interaction model. CI = confidence interval



Supplementary Table 7. Adjusted probabilities of receiving myelosuppressive therapy by age

| Category      | 2019                    |                         |                           | 2020                    |                         |                           | Difference in differences |
|---------------|-------------------------|-------------------------|---------------------------|-------------------------|-------------------------|---------------------------|---------------------------|
|               | Jan 1-Mar 8             | Apr 8-Jul 31            | Difference                | Jan 1-Mar 8             | Apr 8-Jul 31            | Difference                | 2020-2019                 |
|               | Est (95% CI)            | Est (95% CI)            | Est (95% CI)              | Est (95% CI)            | Est (95% CI)            | Est (95% CI)              | Est (95% CI)              |
| Age >75 years | 0.593<br>(0.534, 0.652) | 0.542<br>(0.469, 0.616) | -0.051<br>(-0.109, 0.007) | 0.582<br>(0.539, 0.625) | 0.538<br>(0.488, 0.588) | -0.044<br>(-0.090, 0.001) | 0.007<br>(-0.067, 0.081)  |
| Age ≤75 years | 0.747<br>(0.701, 0.793) | 0.726<br>(0.671, 0.781) | -0.021<br>(-0.058, 0.016) | 0.730<br>(0.697, 0.762) | 0.731<br>(0.698, 0.764) | 0.001<br>(-0.026, 0.028)  | 0.022<br>(-0.021, 0.064)  |

<sup>a</sup> Results are from age:period interaction model. CI = confidence interval

Supplementary Table 8. Adjusted probability of treatment within 30 days using state-specific COVID-19 period exposure dates

| Model and category | 2019                    |                         |                          | 2020                    |                         |                          | Difference in differences |
|--------------------|-------------------------|-------------------------|--------------------------|-------------------------|-------------------------|--------------------------|---------------------------|
|                    | Pre SAHO                | Post SAHO               | Difference               | Pre SAHO                | Post SAHO               | Difference               | 2020-2019                 |
|                    | Est (95% CI)            | Est (95% CI)            | Est (95% CI)             | Est (95% CI)            | Est (95% CI)            | Est (95% CI)             | Est (95% CI)              |
| Unadjusted         | 0.453<br>(0.431, 0.473) | 0.432<br>(0.417, 0.447) | —                        | 0.457<br>(0.434, 0.478) | 0.470<br>(0.453, 0.486) | —                        | —                         |
| Adjusted           |                         |                         |                          |                         |                         |                          |                           |
| Combined           | 0.424<br>(0.336, 0.512) | 0.443<br>(0.340, 0.546) | 0.019<br>(-0.030, 0.068) | 0.439<br>(0.323, 0.555) | 0.483<br>(0.379, 0.587) | 0.044<br>(0.014, 0.074)  | 0.025<br>(-0.042, 0.092)  |
| Breast             | 0.552<br>(0.399, 0.705) | 0.576<br>(0.344, 0.808) | 0.024<br>(-0.172, 0.219) | 0.607<br>(0.427, 0.787) | 0.650<br>(0.542, 0.758) | 0.043<br>(-0.101, 0.187) | 0.019<br>(-0.266, 0.304)  |
| Colorectal         | 0.407<br>(0.316, 0.499) | 0.424<br>(0.313, 0.535) | 0.017<br>(-0.082, 0.116) | 0.422<br>(0.269, 0.575) | 0.446<br>(0.332, 0.560) | 0.024<br>(-0.050, 0.099) | 0.007<br>(-0.156, 0.171)  |
| NSCLC              | 0.400<br>(0.313, 0.487) | 0.403<br>(0.316, 0.489) | 0.003<br>(-0.052, 0.058) | 0.404<br>(0.282, 0.526) | 0.450<br>(0.325, 0.574) | 0.046<br>(0.020, 0.071)  | 0.043<br>(-0.018, 0.103)  |
| Pancreatic         | 0.549<br>(0.321, 0.777) | 0.592<br>(0.430, 0.755) | 0.044<br>(-0.215, 0.302) | 0.533<br>(0.389, 0.677) | 0.559<br>(0.373, 0.744) | 0.026<br>(-0.215, 0.266) | -0.018<br>(-0.342, 0.307) |
| Prostate           | 0.362<br>(0.201, 0.524) | 0.388<br>(0.168, 0.608) | 0.026<br>(-0.284, 0.336) | 0.359<br>(0.178, 0.540) | 0.454<br>(0.312, 0.595) | 0.094<br>(-0.148, 0.337) | 0.069<br>(-0.465, 0.602)  |
| RCC                | 0.353<br>(0.207, 0.499) | 0.403<br>(0.202, 0.604) | 0.050<br>(-0.158, 0.257) | 0.405<br>(0.168, 0.642) | 0.465<br>(0.340, 0.590) | 0.060<br>(-0.108, 0.227) | 0.010<br>(-0.307, 0.327)  |
| UCC                | 0.357<br>(0.242, 0.472) | 0.418<br>(0.260, 0.576) | 0.061<br>(-0.088, 0.210) | 0.400<br>(0.233, 0.568) | 0.441<br>(0.310, 0.571) | 0.040<br>(-0.151, 0.232) | -0.021<br>(-0.244, 0.202) |

<sup>a</sup> Results are from cancer type:period interaction model. Washout period defined using state stay-at-home order dates. SAHO = Stay at home order. NSCLC = Non-small cell lung carcinoma; RCC = renal cell carcinoma; UCC = urothelial cell carcinoma; Est = estimate; CI = 95% confidence interval

Supplementary Table 9. Adjusted probability of receiving myelosuppressive treatment using state-specific COVID-19 period exposure dates

| Model and category | 2019                    |                         |                           | 2020                    |                         |                            | Difference in differences |
|--------------------|-------------------------|-------------------------|---------------------------|-------------------------|-------------------------|----------------------------|---------------------------|
|                    | Pre SAHO                | Post SAHO               | Difference                | Pre SAHO                | Post SAHO               | Difference                 | 2020-2019                 |
|                    | Est (95% CI)            | Est (95% CI)            | Est (95% CI)              | Est (95% CI)            | Est (95% CI)            | Est (95% CI)               | Est (95% CI)              |
| Unadjusted         | 0.687<br>(0.651, 0.723) | 0.676<br>(0.622, 0.729) | -0.012<br>(-0.059, 0.036) | 0.691<br>(0.656, 0.727) | 0.658<br>(0.626, 0.690) | -0.033<br>(-0.062, -0.004) | -0.022<br>(-0.081, 0.038) |
| Adjusted           |                         |                         |                           |                         |                         |                            |                           |
| Combined           | 0.698<br>(0.651, 0.744) | 0.667<br>(0.609, 0.725) | -0.031<br>(-0.065, 0.002) | 0.683<br>(0.651, 0.714) | 0.668<br>(0.633, 0.702) | -0.015<br>(-0.038, 0.008)  | 0.016<br>(-0.026, 0.058)  |
| Breast             | 0.815<br>(0.746, 0.883) | 0.776<br>(0.701, 0.851) | -0.039<br>(-0.122, 0.044) | 0.827<br>(0.783, 0.870) | 0.807<br>(0.767, 0.848) | -0.019<br>(-0.073, 0.034)  | 0.020<br>(-0.077, 0.116)  |
| NSCLC              | 0.835<br>(0.797, 0.872) | 0.808<br>(0.761, 0.856) | -0.026<br>(-0.071, 0.018) | 0.807<br>(0.773, 0.841) | 0.783<br>(0.749, 0.817) | -0.024<br>(-0.059, 0.012)  | 0.003<br>(-0.056, 0.061)  |
| Prostate           | 0.046<br>(0.000, 0.101) | 0.025<br>(0.004, 0.045) | -0.022<br>(-0.080, 0.036) | 0.025 (0.008,<br>0.042) | 0.041<br>(0.012, 0.071) | 0.016<br>(-0.015, 0.047)   | 0.037<br>(-0.025, 0.100)  |
| UCC                | 0.558<br>(0.452, 0.664) | 0.497<br>(0.402, 0.593) | -0.061<br>(-0.190, 0.068) | 0.583<br>(0.505, 0.660) | 0.589<br>(0.518, 0.661) | 0.007<br>(-0.081, 0.095)   | 0.068<br>(-0.086, 0.221)  |

<sup>a</sup> Results are from cancer type:period interaction model. Washout period defined using state stay-at-home order dates. SAHO = Stay at home order. NSCLC = Non-small cell lung carcinoma; UCC = urothelial cell carcinoma; Diff = difference between post SAHO and pre SAHO probabilities; Est = estimate; CI = 95% confidence interval

## Supplementary Figure

Supplementary Figure 1. CONSORT diagram. <sup>a</sup> NCCN = National Comprehensive Cancer Network; NSCLC = Non-small cell lung carcinoma

|       | Criteria   | Patients lost | Patients remaining |
|-------|--|---------------|--------------------|
|       | Total unique patients  |               | 164,188            |
|       | Exclude patients outside of study frame (all patients not diagnosed in Jan-Jul 2019 or Jan-Jul 2020)       | 143,927       | 20,261             |
|       | Exclude patients with no structured activity within 90 days of diagnosis                                   | 1,631         | 18,630             |
|       | Exclude patients with <2 observations after diagnoses  | 1,275         | 17,355             |
|       | Exclude patients with multiple malignancies (only study cohorts considered)                                | 66            | 17,289             |
|       | Treatment begins prior to advanced diagnosis   | 682           | 16,607             |
|       | Exclude patients on non-NCCN recommended therapy or a therapy that involved a clinical study drug          | 344           | 16,263             |
|       | Washout  | 2,127         | 14,136             |
| Aim 2 | Excluded patients who were not diagnosed with breast cancer, prostate cancer, urothelial cancer, or NSCLC. | 4,603         | 9,533              |
|       | Excluded patients not treated within 60 days of advanced diagnosis.  | 2,812         | 6,721              |
|       | Excluded patients who received targeted therapy  | 759           | 5,962              |